1. Home
  2. NGNE vs SUPX Comparison

NGNE vs SUPX Comparison

Compare NGNE & SUPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$31.76

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

SUPX

Super X AI Technology Limited Ordinary Shares

HOLD

Current Price

$10.47

Market Cap

336.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
SUPX
Founded
2003
2021
Country
United States
Singapore
Employees
N/A
40
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
336.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
SUPX
Price
$31.76
$10.47
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
151.5K
324.3K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.65
$6.61
52 Week High
$37.27
$76.00

Technical Indicators

Market Signals
Indicator
NGNE
SUPX
Relative Strength Index (RSI) 64.15 63.43
Support Level $18.25 $9.80
Resistance Level $32.02 $10.91
Average True Range (ATR) 2.33 0.87
MACD 0.17 0.30
Stochastic Oscillator 68.50 96.66

Price Performance

Historical Comparison
NGNE
SUPX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

Share on Social Networks: